Kornimate/medical-research-clean huggingface dataset:
an act group intervention for ed-patients

Conditions: Eating Disorder

Summary: the purpose of this study was to test if an act group intervention focusing on body image reduces eating disorders symptoms and reduces care consumption in patients treated at a specialised eating disorder unit.

the study is an rct in which the act-intervention is compared to treatment as usual. the trial started in 2010, and randomisation of patients continued until 2014, and follow-ups was completed in 2016. according to analysis of power, a total of 120 patients needed to be included, 60 in each arm. patients eligible for the interventions were invited to participate after their clinician reported them to the head investigator. the head investigator sent a letter to the patients with information on the study. the clinician then asked the patient if the letter had been read. if the patient wanted to participate, he/she was invited to an information and assessment meeting. the head investigator made sure that the patient understood the information, and what each study arm might mean for the patient when participating. consent to participate was collected both verbally and in writing. at this meeting the patient received an envelope which contained the randomisation outcome. the patient then received information regarding the continued treatment according to which research arm he/she was to participate in. the participants randomised to treatment as usual continued with the treatment as planned before enrolment. participants in the intervention arm started the group intervention consisting of 12 sessions over a period of three to four months. the intervention also included one individual meeting with the group-leaders before and one after the intervention. the intervention is a manualised application of the book "lev med din kropp" \[live with your body\]. participants who were in need of further care after the intervention were offered continued treatment accordingly at the clinic. if a participant chose to terminate the intervention, or deteriorated during the intervention to the point that other treatment was needed, further treatment was agreed upon in dialogue with the patient. if needed, further assessment and physical examination was conducted in accordance to the clinics standard procedures. data was collected at four times for all participants. at treatment start and end, and follow-up at 12 and 24 months after inclusion. at each time, the participants were prompted to fill in five different self-assessment forms.

Eligibility criteria:
inclusion criteria: * diagnosed with an eating disorder according to dsm-iv (apa, 1994) * enrolled as a patient at eriksbergsgarden, a clinic in sweden offering specialized care for patients with an eating disorder * attained a somewhat regular eating pattern consisting of at least three meals per day exclusion criteria: * having physical or psychiatric complicating factors of such severity that these conditions needed to be addressed during the treatment period (12 weeks).

Keywords: eating disorders acceptance and commitment therapy body image
comparison of two different sedation protocols during transvaginal oocyte retrieval

Conditions: Infertility

Summary: the effects of two different sedation protocols during transvaginal oocyte retrieval will be investigated on propofol consumption as a rescue sedative and on ivf success. one group will receive dexmedetomidine and fentanyl while the other will receive midazolam and remifentanil.

women will be consecutively allocated into one of the following two groups using a 1:1 ratio in order to avoid any potential source of bias. group dex: women will receive dexmedetomidine (solution 4 γ/ml) continuously infused at a dose of 1 γ/kg/ and fentanyl 100γ iv. dexmedetomidine infusion will start 10 min before the start of transvaginal oocyte retrieval and will stop at the end of procedure. at that time point, both total volume (ml) and dose (γ) of dexmedetomidine administered will be recorded. group mzm: women will receive remifentanil (solution 50γ/ml) continuously infused at a dose of 0.2 γ/kg/min και midazolam 1 mg iv. remifentanil infusion will start 10 min before the start of transvaginal oocyte retrieval and will stop at the end of the procedure. at that time point, both total volume (ml) and dose (γ) of remifentanil administered will be recorded. in both groups, in case of non-co-operation of the woman (e.g. kinetic response), propofol will be given as a bolus rescue dose as follows: the 1st rescue dose will be 1mg/kg while all the next doses will be 0.5 mg/kg. at the end of the procedure, the number of rescue doses and the total rescue dose (mg) of propofol given will be recorded. intraoperative monitoring will include ecg, noninvasive blood pressure, spo2, etco2 and depth of sedation using bis values and οαss scale. also, adverse effects such as hypotension, bradycardia, nausea \& vomiting, rigidity, airway obstruction, and need for bag-mask ventilation will be recorded. the use of vasoactive drugs will also be reported. at the end of the procedure, the time and quality of recovery will be assessed using οαss scale (max score=5), while postoperatively the post anesthesia discharge scoring system, as well as woman's and gynecologist's (physician) overall satisfaction related to the sedation techniques used, will be recorded. regarding the ivf outcome, the following parameters will be recorded: number of oocytes retrieved, the percentage of mature oocytes, embryo quality, percentage of positive pregnancy test, percentage of clinical pregnancy, the percentage of live birth.

Eligibility criteria:
inclusion criteria: * female patients between 25 and 45 years old that do not meet any of the exclusion criteria exclusion criteria: * patient refusal, epilepsy, gerd, morbid obesity, drug allergy, asa class \>2, severe hypotension or bradycardia, presence of atrioventricular block, cerebrovascular disease or hepatic dysfunction

Keywords: transvaginal oocyte retrieval sedation dexmedetomidine fentanyl remifentanil midazolam
non-significant risk (nsr) study of [68ga]-psma-11 (illuccix) as a bgrt bioguide on reflexion x1

Conditions: Prostate Cancer

Summary: to qualitatively determine the imaging performance of pet-ct imaging subsystem of the reflexion x1 system device in patients undergoing standard-of-care (soc) \[68ga\]-psma-11 pet-ct using illuccix on the same day.

in this non-significant risk (nsr) study, investigators will perform imaging only (no treatment) on the x1 platform immediately following an already planned pet/ct diagnostic imaging using illuccix for standard of care indications in men with prostate cancer of various stages. this approach will be used to assess imaging performance of the x1 in comparison to diagnostic imaging scanners. evidence from this study will supplement and enhance technical understanding of the psma-11-guided bgrt delivery in the setting of prostate cancer. as such, the patient population selected for this investigation is meant to optimally represent the spectrum of cases, with respect to motion and radiographic environment that a radiation oncologist may encounter in practice.

Eligibility criteria:
inclusion criteria: * men with prostate adenocarcinoma undergoing standard of care psma-pet imaging for initial staging or re-staging at suspected relapse/progression exclusion criteria: * 1. known psychiatric or substance abuse disorder which in the opinion of the investigator would interfere with study conduct 2. patient weight exceeding 450 lb (weight limit of reflexion x1 system) 3. uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements.
universal screening program for cytomegalovirus infection in the first trimester of pregnancy (citemb study)

Conditions: Screening

Summary: the aim of this study is to evaluate a universal ccmv screening programme in the first trimester of pregnancy in primary care in catalonia (spain).

this is the pilot study of implementation of the cmv universal screening program in the first trimester of pregnancy barcelona and its metropolitan area. general objective the aim of this study is to evaluate a universal cmv screening programme in the first trimester of pregnancy in primary care. specific aims of this pilot study: 1. estimate the percentage of acceptance of cmv screening in the population 2. to observe and to determine the rate of cmv primary infection in the first trimester of pregnancy 3. to identify and describe the rate of the vertical fetal infection detected through the amniocentesis of the 2nd trimester 4. to identify and describe the rate of fetal sequelae (due to the primary cmv infection in the first trimester), obtained by imaging techniques (ultrasound and mri) 5. to identify and describe the rate of neonatal infection (congenital cmv) 6. to identify and describe the rate of sequelae for congenital cmv at one year of the child's age 7. to identify and describe the percentage rate of top following the diagnosis of primary infection on cmv 8. to identify and describe the rate of legal of top following the diagnosis of fetal infection 9. to identify and describe the rate of top following the diagnosis of fetal anomalies 10. to obtain and describe the annual cost of cmv screening in the first quarter in catalonia (spain).

Eligibility criteria:
inclusion criteria: * maternal age 16 years or older, and * gestational age less than 14 weeks. exclusion criteria: * language barrier preventing informed consent, * gestational age at blood sampling above 14 weeks, and * consent withdrawal

Keywords: universal screening pregnancy cytomegalovirus vertical transmission child health prevention
genetics of peripheral artery genomics

Conditions: Peripheral Artery Disease

Summary: peripheral artery disease is a disease that contributes to significant morbidity and mortality of millions of americans yearly. very little is known about the pathophysiology of atherosclerosis in peripheral artery disease. we plan to collect peripheral arteries and muscle tissue from patients undergoing amputation for end stage peripheral arterial occlusive disease. by extracting the rna from these arteries and tissues and comparing them with rna expression from normal arteries, we hope to have a better understanding of the pathophysiology of atherosclerosis in this setting. we aim to prove the hypothesis that a novel gene expression pattern can be discovered by the successful extraction of rna from plaques from human peripheral arteries.

patients scheduled to undergo lower extremity amputation will be consented for extraction of plaque from the carotid artery or arterial tissue from the amputated limbs. the surgeon will perform the amputation, then the harvest team will collect arterial tissue from amputated limbs. these samples will be immersed in rnalater solution to preserve the integrity of the rna. tissues will stored at -80oc in the rnalater until the rna is later extracted using a standardized protocol. the rna will be examined for quality using an agilent bioanalyzer, and will then be processed on affymetrix u133a chips for gene expression data. the data will be analyzed with the matlab software package.

Eligibility criteria:
inclusion criteria: * patients undergoing amputations for peripheral artery disease * patients undergoing free fibular transfer exclusion criteria: * those that are not able to consent to the study

Keywords: smoking hypertension diabetes cardiovascular disease renal failure
impact evaluation of agribusiness support and nutrition services projects in upper egypt

Conditions: Poverty, Low Income, Food Insecurity, Undernutrition

Summary: this project seeks to evaluate the impact of two usaid-funded projects that are implemented in rural upper egypt. the first project is the feed the future egypt, food-security and agribusiness support (fas) project; the second project is the improving maternal, child health, and nutrition services (imchn) project. the specific study objectives are (1) to estimate the impact of fas interventions on project outcome indicators-especially on household income (measured by total household expenditure), household food security, and maternal and child nutrition-among farm households; (2) to estimate the effects of imchn interventions on maternal and child health and nutrition knowledge among community health workers (chws) and among farm households; and (3) to analytically explore potential synergistic effects of fas and imchn interventions on maternal and child nutrition among farm households being exposed to both projects.


Eligibility criteria:
inclusion criteria (will follow those of the usaid-funded fas program). in oct 2017, known to be: * farmers with 10 feddans or less per household * farmers who have experience or interest in horticulture production. exclusion criteria: * farmers with more than 10 feddans per household * farmers with no interest in horticulture production
genetic origin of lipid disorders

Conditions: Lipid Disorder

Summary: several lipid disorders are without known genetic origin. the scope of this project is to sequence genes superior involved in lipid and carbohydrate metabolism in patients with severe lipid disorders. the resulting mutations will be tested in suitable in vitro systems to detect their part in development of the specific disease.

see "brief summary" above.

Eligibility criteria:
inclusion criteria: * proven written informed consent prior to recruitment * male or female * 18-55 years old * patients with severe lipid disorders * fasting plasma cholesterol, triglyceride or glucose, blood pressure or waist circumference/bmi out of normal range exclusion criteria: -

Keywords: lipid disorder gene mutation
comparison of efficacy of azithromycin and levamisole versus of azithromycin in in the treatment of acne

Conditions: Acne

Summary: different immunologic mechanisms contribute to development of inflammation in acne vulgaris and immunologic effect of levamisole has been demonstrated. objective: the aim of this study was to compare azithromycin and levamisole with azithromycin alone in the treatment of acne vulgaris.

an investigator blind clinical randomized prospective two months study was designed. one hundred sixty nine acne patients presenting in our outpatients clinic were randomly allocated to two treatment groups: azithromycin and levamisole ( group 1 ) and azithromycin alone ( group 2 ) .one hundred forty eight patients completed the duration of the study and their clinical responses were evaluated and compared by using monthly photographic records .

Eligibility criteria:
inclusion criteria: 1. patients who had at least 20 papules and/or pustules, 2. patients with nodule and/or cyst disregarding the number of papules of pustules, were included the study. there was not any age limit exclusion criteria: 1. were using any type of systemic treatment for their acne at the time of visit or during the last month; 2. had any hematological, renal or hepatic disease 3. were pregnant or lactating; 4. had drug-induced acne; 5. were using alcohol, anti-convulsants or anti-coagulants.
a clinical comparison of two daily disposable contact lenses.

Conditions: Myopia

Summary: the objective of this study is to evaluate the clinical performance of two daily disposable contact lenses.


Eligibility criteria:
inclusion criteria: * age: 18 years to 45 years * current daily soft contact lens as habitual optical correction: * refraction: * best sphere (corrected for back vertex distance) -1.00 to -6.00d * cylinder 0.00 to - 0.75d * best spectacle corrected visual acuity of 6/9 or better in each eye * willingness to adhere to the instructions set in the clinical protocol * signature of the subject on the informed consent form exclusion criteria: * systemic or ocular allergies which might interfere with contact lens wear * systemic disease which might interfere with contact lens wear * ocular disease which might interfere with contact lens wear (e.g. hypoesthesia, insufficient lacrimal secretion) * use of medication which might interfere with contact lens wear * active ocular infection * use of ocular medication * significant ocular anomaly * presence of two or more corneal scars in either eye * pregnancy or lactation * any medical condition that might be prejudicial to the study * participated in any other clinical studies in the past month * currently wears monovision
milrinone on right ventricular strain in cardiac surgery

Conditions: Ischemic Heart Disease; Valvular Heart Disease

Summary: the purpose of this study is to analyze the changes in right ventricular strain before and after milrinone administration in order to find out whether milrinone improves rv systolic performance in patients undergoing cardiac surgery.


Eligibility criteria:
inclusion criteria: * patient agree and provide written informed consent. * patient undergoing elective cardiac surgery * preoperative lv ef\>50% (tte) exclusion criteria: * preoperative cardiac dysrhythmia * preoperative iabp * use of other inotropic agents

Keywords: milrinone strain systolic function
influence of variable inflow volume, dwell duration and glucose concentration on ultrafiltration volume in apd patients

Conditions: Renal Failure; Chronic Kidney Diseases

Summary: the purpose of the current investigation is to provide proof of concept for a future approach to improve uf prediction accuracy. while building on the ideas of the past, the concept is augmented by leveraging additional diagnostic technologies and digital data analytics methodologies.

the primary objective of this study is: - ufv determined per defined dwells with variable dwell duration, dialysis fluid glucose composition and inflow volumes the secondary objectives of this study are: * mean daily ufv * defined laboratory parameter like urea, creatinine, glucose, sodium determined in blood and dialysate during the extended pet (in dialysate additionally determination: phosphate, albumin removal) * treatment parameter: performed treatment duration and volume * fluid status measured by body composition monitor (bcm) * manual ipp determination during the extended pet: at the first half of the dwell (during the first hour) for every 20 min and during the second half after 2h, 3h and 4h dwell time * residual renal function (rrf): renal urea and creatinine clearance, 24h urine output, glomerular filtration rate (gfr) * extended pet * 24 h batch collection (including e.g. total peritoneal clearance) * analysis of daily dietetic fluid intake, weight and further parameters documented by the patient in a patient diary

Eligibility criteria:
inclusion criteria: * informed consent signed and dated by study patient and investigator/ authorized physician * patients between 18-65 of age * chronic kidney disease (ckd) patients being treated with nocturnal apd for at least 3 months * ability to understand the nature and requirements of the study * total kt/v ≥ 1.7 (counting from recruitment of the patient the measurement should not be older than 3 months) * apd patients using sleep•safe pd-cycler or sleep•safe harmony pd-cycler with an ipp ≤ 18 cm h2o for the fill volume of 120% exclusion criteria: * any condition which could interfere with the patient's ability to comply with the study * patients who have any condition prohibiting the use of bcm, like patients with major amputations (e.g. lower leg) * patients who have been subject to peritonitis/ exit site infection during the last 4 weeks * women of childbearing age without effective means of contraception, pregnancy (pregnancy test will be conducted at start and end of study) or lactation period * life expectancy \< 3 months * patients suffering from uncontrolled/ not well adjustable diabetes * recent history of drain related problems, catheter malfunction, or frequent alarms during treatment * patients with uncontrolled hypertension and/ or previous history of vascular instability during pd * patients treated with intermittent apd * participation in an interventional clinical study during the preceding 30 days * previous participation in the same study * apd patients having dwell exchanges throughout the day ("day dwell")

Keywords: renal replacement therapy peritoneal dialysis automated peritoneal dialysis pd cycler
cladribine, cytarabine and idarubicin in patients with relapsed acute myelocytic leukemia (aml)

Conditions: Leukemia, Myelocytic, Acute

Summary: the purpose of this study is to evaluate the safety and the efficacy of cladribine, high-dose cytarabine and idarubicin in the treatment of patients with relapsed acute myeloid leukemia.

considerable progress has been made in the induction therapy of acute myeloid leukemia (aml); however, current therapeutic results are still unsatisfactory in those with relapsed disease. the purine nucleoside analogue cladribine (2-chlorodeoxyadenosine, 2-cda) has been shown to be a safe and active agent in acute myeloid leukemia. synergistic interaction between cladribine and cytarabine has been demonstrated in preclinical and clinical studies. the current multicenter phase ii study was initiated to evaluate the efficacy and toxicity of cladribine, high-dose cytarabine, and idarubicin in the treatment of patients with relapsed aml. adult patients of all age groups can be enrolled in the trial, but elderly patients will be treated with a less dose-intensive regimen.

Eligibility criteria:
inclusion criteria: * patients with relapsed aml with a remission duration of at least 6 months after first complete remission (cr) or of at least 3 months after second (or higher) cr * age \>= 18 years * life expectancy of at least three months (without consideration of aml and complications) * eastern cooperative oncology group (ecog) 0-2 (without consideration of aml and complications) * written informed consent exclusion criteria: * prior therapy of aml with cladribine * severe, uncontrolled infection at time of inclusion (enrollment is possible after control of infection) * cardiac insufficiency grade iii or iv new york heart association (nyha) * severe renal insufficiency with a clearance of \< 30 ml/min (if not due to aml) * severe hepatic insufficiency with bilirubin \> 3 mg/dl or ast \> 200 u/l (if not due to aml) * other severe organ impairment grade iii or iv world health organization (who) (if not due to aml or, in the opinion of the investigator, may not interfere with the procedures in the study) * hiv infection * intolerance to study drugs * pregnant or breast-feeding women * any other malignant disease which will probably affect the course of aml

Keywords: aml, relapsed cladribine chemotherapy